Cornelia Eckert

Dr. Cornelia Eckert


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in The Lancet
Verified
Journal Article
Closed access
PDF file
CECornelia Eckert
Cornelia Eckert
ABAndrea Biondi
Andrea Biondi
KSKarlheinz Seeger
Karlheinz Seeger
GCGiovanni Cazzaniga
Giovanni Cazzaniga
RHReinhard Hartmann
Reinhard Hartmann
GHGünter Henze
Günter Henze

20 July 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CECornelia Eckert
Cornelia Eckert
GHGünter Henze
Günter Henze
KSKarlheinz Seeger
Karlheinz Seeger
NHNikola Hagedorn
Nikola Hagedorn
GMGeorg Mann
Georg Mann
ASArend von Stackelberg
Arend von Stackelberg
Purpose: In children with intermediate risk of relapse of acute lymphoblastic leukemia (ALL), it is essential to identify patients in need of treatment intensification. We hypothesized that the prognosis of patients with unsatisfactory reduction of minimal residual disease (MRD) can be improved by allogeneic hematopoietic stem-cell transplantation (HSCT). Patients and Methods: In the Acute Lymphoblastic Leukemia–Relapse Study of the Berlin-Frankfurt-Münster Group (ALL-REZ BFM) 2002, patients with an MRD level of ≥ 10−3 (n = 99) at the end of induction therapy were allocated to HSCT, whereas those with an MRD level less than 10−3 (n = 109) continued to receive chemotherapy. MRD was quantified by real-time polymerase chain reaction for clone-specific T-cell receptor/immunoglobulin gene rearrangements. Results: The probability of event-free survival for patients with MRD ≥ 10−3 was 64% ± 5% in ALL-REZ BFM 2002 compared with 18% ± 7% in the predecessor study ALL-REZ BFM P95/96 (P < .001). This was mainly achieved by reducing the cumulative incidence of subsequent relapse (CIR) at 8 years from 59% ± 9% to 27% ± 5% (P < .001). The favorable prognosis of patients with MRD less than 10−3 could be confirmed in those with a late combined or isolated bone marrow B-cell precursor (BCP) –ALL relapse (CIR, 20% ± 5%), whereas patients with an early combined BCP-ALL relapse had an unfavorable outcome (CIR, 63% ± 13%; P < .001). Conclusion: Allogeneic HSCT markedly improved the prognosis of patients with intermediate risk of relapse of ALL and unsatisfactory MRD response. As a result, outcomes in this group approximated those of patients with favorable MRD response. Patients with early combined relapse require treatment intensification even in case of favorable MRD response, demonstrating the prognostic impact of time to relapse.

1 April 2013 in European Journal of Cancer
Verified
Journal Article
Closed access
CECornelia Eckert
Cornelia Eckert
ASArend von Stackelberg
Arend von Stackelberg
KSKarl Seeger
Karl Seeger
TGTom W.L. Groeneveld
Tom W.L. Groeneveld
CPChristina Peters
Christina Peters
GHGünter Henze
Günter Henze

1 July 2021 in European Journal of Cancer
Verified
Journal Article
Open access
CECornelia Eckert
Cornelia Eckert
CPCatriona Parker
Catriona Parker
AMAnthony V. Moorman
Anthony V. Moorman
JIJulie Ae. Irving
Julie Ae. Irving
RKRenate Kirschner-Schwabe
Renate Kirschner-Schwabe
VSVaskar Saha
Vaskar Saha
Outcomes of children with high-risk (HR) relapsed acute lymphoblastic leukaemia (ALL) (N = 393), recruited to ALLR3 and ALL-REZ BFM 2002 trials, were analysed. Minimal residual disease (MRD) was assessed after induction and at predetermined time points until haematopoietic stem cell transplantation (SCT). Genetic analyses included karyotype, copy-number alterations and mutation analyses. Ten-year survivals were analysed using Kaplan-Meier and Cox models for multivariable analyses. Outcomes of patients were comparable in ALLR3 and ALL-REZ BFM 2002. The event-free survival of B-cell precursor (BCP) and T-cell ALL (T-ALL) was 22.6% and 26.2% (P = 0.94), respectively, and the overall survival (OS) was 32.6% and 28.2% (P = 0.11), respectively. Induction failures (38%) were associated with deletions of NR3C1 (P = 0.002) and BTG1 (P = 0.03) in BCP-ALL. The disease-free survival (DFS) and OS in patients with good vs poor MRD responses were 57.4% vs 22.6% (P < 0.0001) and 57.8% vs 32.0% (P = 0.0004), respectively. For BCP- and T-ALL, the post-SCT DFS and OS were 42.1% and 56.8% (P = 0.26) and 51.6% and 55.4% (P = 0.67), respectively. The cumulative incidences of post-SCT relapse for BCP- and T-ALL were 36.9% and 17.8% (P = 0.012) and of death were 10.7% and 25.5% (P = 0.013), respectively. Determinants of outcomes after SCT were acute graft versus host disease, pre-SCT MRD (≥10-3), HR cytogenetics and TP53 alterations in BCP-ALL. Improvements in outcomes for HR ALL relapses require novel compounds in induction therapy to improve remission rates and immune targeted therapy after induction to maintain remission after SCT. ALLR3: NCT00967057; ALL REZ-BFM 2002: NCT00114348.

7 July 2022 in Blood
Verified
Journal Article
Closed access
PDF file
KMKristina Müller
Kristina Müller
FVFotini Vogiatzi
Fotini Vogiatzi
DWDorothee Winterberg
Dorothee Winterberg
TRThies Rösner
Thies Rösner
LLLennart Lenk
Lennart Lenk
DSDenis Martin Schewe
Denis Martin Schewe
Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting children. Although therapeutic strategies have improved, T-cell acute lymphoblastic leukemia (T-ALL) relapse is associated with chemoresistance and a poor prognosis. One strategy to overcome this obstacle is the application of monoclonal antibodies. Here, we show that leukemic cells from patients with T-ALL express surface CD38 and CD47, both attractive targets for antibody therapy. We therefore investigated the commercially available CD38 antibody daratumumab (Dara) in combination with a proprietary modified CD47 antibody (Hu5F9-IgG2σ) in vitro and in vivo. Compared with single treatments, this combination significantly increased in vitro antibody-dependent cellular phagocytosis in T-ALL cell lines as well as in random de novo and relapsed/refractory T-ALL patient-derived xenograft (PDX) samples. Similarly, enhanced antibody-dependent cellular phagocytosis was observed when combining Dara with pharmacologic inhibition of CD47 interactions using a glutaminyl cyclase inhibitor. Phase 2–like preclinical in vivo trials using T-ALL PDX samples in experimental minimal residual disease–like (MRD-like) and overt leukemia models revealed a high antileukemic efficacy of CD47 blockade alone. However, T-ALL xenograft mice subjected to chemotherapy first (postchemotherapy MRD) and subsequently cotreated with Dara and Hu5F9-IgG2σ displayed significantly reduced bone marrow infiltration compared with single treatments. In relapsed and highly refractory T-ALL PDX combined treatment with Dara and Hu5F9-IgG2σ was required to substantially prolong survival compared with single treatments. These findings suggest that combining CD47 blockade with Dara is a promising therapy for T-ALL, especially for relapsed/refractory disease harboring a dismal prognosis in patients.

28 April 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
FLFranco Locatelli
Franco Locatelli
CECornelia Eckert
Cornelia Eckert
OHOndrej Hrusak
Ondrej Hrusak
BBBarbara Buldini
Barbara Buldini
MSMary Sartor
Mary Sartor
ASArend von Stackelberg
Arend von Stackelberg
Background: Blinatumomab, a CD3/CD19 BiTE® (bispecific T cell engager) molecule, was superior to high‐risk third course consolidation chemotherapy (HC3) in prolonging event‐free survival (EFS) in children with high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia (B‐ALL). Here, we report results from a post hoc measurable residual disease (MRD) analysis of this phase 3 study (NCT02393859).Procedure: Children >28 days and <18 years with high‐risk first‐relapse B‐ALL in cytomorphological complete remission (M1 marrow, <5% blasts) or with M2 marrow (≥5% and <25% blasts) after induction and two cycles of high‐risk consolidation chemotherapy (baseline) were enrolled in this trial. Patients received one cycle of blinatumomab (15 μg/m2/day, 4 weeks, continuous intravenous infusion) or HC3. The primary endpoint was EFS. In this post hoc analysis, patients with MRD <10–4 by PCR were grouped as having positive but not quantifiable (pbnq) or undetectable disease.Results: A higher proportion of patients with MRD <10–4 had undetectable versus pbnq disease after blinatumomab (day 29) than after HC3 (p = 0.0367). Of the 22 patients with MRD ≥10–4 at baseline who achieved MRD remission after blinatumomab, 20 (91%) achieved MRD <10–4 remission by day 15. Patients treated with blinatumomab had improved EFS and overall survival compared with those treated with HC3 independent of end‐of‐induction or baseline (end‐of‐second consolidation) MRD levels.Conclusions: Blinatumomab was more efficacious than HC3 regardless of MRD status before treatment. These data support the role of blinatumomab in inducing deep MRD remission, negating the poor prognostic value of MRD.